Biotechnology startup Ginkgo Bioworks is in talks to go public through a merger with a blank-check firm backed by Harry Sloan, in a transaction valued at around $20 billion, Bloomberg News reported on Friday, citing people with knowledge of the matter.
Ginkgo Bioworks did not immediately respond to a Reuters request for comment.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
{{#Source}}{{Source}}{{/Source}}{{#IsBlog}}
{{ImageCopyright}}
{{Disclaimer}}
{{/Disclaimer}}